Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 (PTK/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC)

This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The definitive publisher-authenticated version [Annals of Oncology, 2006, 17(Supplement 9), abstract PD732] is available online at: http://annonc.oxfordjournals.org/. This is an abstract of a paper presented at the 31st ESMO Congress 29 September - 3 October, 2006: Istanbul, Turkey. The published versions lists additional authors.